The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Natural products — The future scaffolds for novel antibiotics?
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Infectious Diseases Society of America
Enders, J. F. (1969) · Journal of Infectious Diseases · doi:10.1093/infdis/119.3.317 · Cited by 3,286
Drug Discovery: A Historical Perspective
Drews, J. (2000) · Science · doi:10.1126/science.287.5460.1960 · Cited by 2,760
The evolving role of natural products in drug discovery
Koehn, F. E., & Carter, G. T. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1657 · Cited by 2,572
The role of natural product chemistry in drug discovery
Butler, M. S. (2004) · Journal of Natural Products · doi:10.1021/np040106y · Cited by 1,381
Self-citationThe influence of natural products upon drug discovery (Antiquity to late 1999)
Newman, D. J., Cragg, G. M., & Snader, K. M. (2000) · Natural Product Reports · doi:10.1039/a902202c · Cited by 1,293
Natural products to drugs: natural product-derived compounds in clinical trials
Butler, M. S. (2008) · Natural Product Reports · doi:10.1039/b514294f · Cited by 1,075
Self-citationWhere will new antibiotics come from?
Walsh, C. (2003) · Nature Reviews Microbiology · doi:10.1038/nrmicro727 · Cited by 755
The future challenges facing the development of new antimicrobial drugs
Coates, A., Hu, Y., Bax, R., & Page, C. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd940 · Cited by 704
Bagley, M. C., Dale, J. W., Merritt, E. A., & Xiong, X. (2005) · Chemical Reviews · doi:10.1021/cr0300441 · Cited by 612
Why is big Pharma getting out of antibacterial drug discovery?
Projan, S. J. (2003) · Current Opinion in Microbiology · doi:10.1016/j.mib.2003.08.003 · Cited by 503
Cited by
Natural products to drugs: natural product-derived compounds in clinical trials
Butler, M. S. (2008) · Natural Product Reports · doi:10.1039/b514294f · Cited by 1,075
Self-citationPlatensimycin is a selective FabF inhibitor with potent antibiotic properties
Wang, J., Soisson, S. M., Young, K., Shoop, W., Kodali, S., Galgoci, A., Painter, R., Parthasarathy, G., Tang, Y. S., Cummings, R., et al. (2006) · Nature · doi:10.1038/nature04784 · Cited by 812
Antibiotics produced by Streptomyces
de Lima Procópio, R. E., da Silva, I. R., Martins, M. K., de Azevedo, J. L., & de Araújo, J. M. (2012) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2012.08.014 · Cited by 735
Physicochemical Properties of Antibacterial Compounds: Implications for Drug Discovery
O’Shea, R., & Moser, H. E. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm700967e · Cited by 689
Novel classes of antibiotics or more of the same?
Coates, A. R., Halls, G., & Hu, Y. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01250.x · Cited by 598
New aspects of natural products in drug discovery
Lam, K. S. (2007) · Trends in Microbiology · doi:10.1016/j.tim.2007.04.001 · Cited by 531
Renaissance in antibacterial discovery from actinomycetes
BALTZ, R. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.04.008 · Cited by 498
The antibiotic resistance crisis, with a focus on the United States
Martens, E., & Demain, A. L. (2017) · The Journal of Antibiotics · doi:10.1038/ja.2017.30 · Cited by 445
Antibiotics in the clinical pipeline in 2013
Butler, M. S., Blaskovich, M. A., & Cooper, M. A. (2013) · The Journal of Antibiotics · doi:10.1038/ja.2013.86 · Cited by 433
Self-citationThe Evolving Role of Chemical Synthesis in Antibacterial Drug Discovery
Wright, P. M., Seiple, I. B., & Myers, A. G. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201310843 · Cited by 426
The value of natural products to future pharmaceutical discovery
Baker, D. D., Chu, M., Oza, U., & Rajgarhia, V. (2007) · Natural Product Reports · doi:10.1039/b602241n · Cited by 413
Al-Worafi, Y. M. (2020) · Drug Safety in Developing Countries · doi:10.1016/b978-0-12-819837-7.00008-x · Cited by 371
LaFayette, S. L., Collins, C., Zaas, A. K., Schell, W. A., Betancourt-Quiroz, M., Gunatilaka, A. A. L., Perfect, J. R., & Cowen, L. E. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1001069 · Cited by 329
“Since natural products and their derivatives are extensively used in medicine and agriculture [8,9], the evolution of resistance to these agents can have profound consequences for human health.”
BackgroundDhingra, S., Rahman, N. A. A., Peile, E., Rahman, M., Sartelli, M., Hassali, M. A., Islam, T., Islam, S., & Haque, M. (2020) · Frontiers in Public Health · doi:10.3389/fpubh.2020.535668 · Cited by 329
Three-dimensional cellular microarray for high-throughput toxicology assays
Lee, M.-Y., Kumar, R. A., Sukumaran, S. M., Hogg, M. G., Clark, D. S., & Dordick, J. S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708756105 · Cited by 314
Natural Products as a Source for Novel Antibiotics
Moloney, M. G. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.05.001 · Cited by 308
Rare actinomycetes: a potential storehouse for novel antibiotics
Tiwari, K., & Gupta, R. K. (2012) · Critical Reviews in Biotechnology · doi:10.3109/07388551.2011.562482 · Cited by 297
Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance.
Cowen, L. E., & Steinbach, W. J. (2008) · Eukaryotic Cell · doi:10.1128/ec.00041-08 · Cited by 285
Developing Aspergillus as a host for heterologous expression
Lubertozzi, D., & Keasling, J. D. (2009) · Biotechnology Advances · doi:10.1016/j.biotechadv.2008.09.001 · Cited by 281
Antibiotics in the clinical pipeline in 2011
Butler, M. S., & Cooper, M. A. (2011) · The Journal of Antibiotics · doi:10.1038/ja.2011.44 · Cited by 272
Self-citationMorin: A Promising Natural Drug
Caselli, A., Cirri, P., Santi, A., & Paoli, P. (2016) · Current Medicinal Chemistry · doi:10.2174/0929867323666160106150821 · Cited by 253
Metadata
- Authors
- Butler, M. S., & Buss, A. D.
- Venue
- Biochemical Pharmacology
- Publisher
- Elsevier BV
- Published
- 2006-03
- Volume
- 71
- Issue
- 7
- Pages
- 919-929
- ISSN
- 0006-2952 (ISSN-L)
- OpenAlex
- W1978970152
- Cited by
- 337
- References
- 66
- FWCI
- 5.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.